Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 56


Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.

Li T, Wang B, Wang Z, Ragaz J, Zhang J, Sun S, Cao J, Lv F, Wang L, Zhang S, Ni C, Wu Z, Xie J, Hu X.

PLoS One. 2015 Jul 17;10(7):e0133133. doi: 10.1371/journal.pone.0133133. eCollection 2015.


Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM.

Lancet Oncol. 2015 Apr;16(4):436-46. doi: 10.1016/S1470-2045(15)70064-1. Epub 2015 Mar 18.


Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, Fan M, Li J, Wang B, Wang Z, Zhang Q, Sun S, Liao C.

Int J Cancer. 2014 Oct 15;135(8):1961-9. doi: 10.1002/ijc.28829. Epub 2014 Mar 20.


The SUVmax for (18)F-FDG correlates with molecular subtype and survival of previously untreated metastatic breast cancer.

Zhang J, Jia Z, Zhou M, Ragaz J, Zhang YP, Wang BY, Wang ZH, Hu XC, Zhang YJ.

Clin Nucl Med. 2013 Apr;38(4):256-62. doi: 10.1097/RLU.0b013e3182816318.


The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer.

Zhang J, Jia Z, Ragaz J, Zhang YJ, Zhou M, Zhang YP, Li G, Wang BY, Wang ZH, Hu XC.

BMC Cancer. 2013 Jan 31;13:42. doi: 10.1186/1471-2407-13-42.


Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?

Ragaz J.

Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S14. doi: 10.1186/bcr2743. No abstract available.


Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.

Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, Shao Z, Zhu J, Guo X, Chen J, Zhu B, Wang Z, Hu X.

Breast Cancer Res Treat. 2010 Dec;124(3):733-43. doi: 10.1007/s10549-010-1183-6. Epub 2010 Sep 30.


Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival.

Woodward WA, Truong PT, Yu TK, Tereffe W, Oh J, Perkins G, Strom E, Meric-Bernstam F, Gonzalez-Angulo AM, Speers C, Ragaz J, Buchholz TA.

Breast Cancer Res Treat. 2010 Sep;123(2):597-605. doi: 10.1007/s10549-010-0829-8. Epub 2010 Mar 20.


Radiation impact in breast cancer.

Ragaz J.

Breast Cancer Res. 2009;11 Suppl 3:S14. doi: 10.1186/bcr2433. Epub 2009 Dec 18. Review. No abstract available.


Adjuvant targeted therapy in early breast cancer.

Mackey J, McLeod D, Ragaz J, Gelmon K, Verma S, Pritchard K, Laing K, Provencher L, Charbonneau LF.

Cancer. 2009 Mar 15;115(6):1154-68. doi: 10.1002/cncr.24114. Review.


Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.

Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C.

Clin Cancer Res. 2006 Apr 15;12(8):2468-75. Erratum in: Clin Cancer Res. 2006 Aug 15;12(16):5002.


Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M.

J Natl Cancer Inst. 2005 Jan 19;97(2):116-26.


Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM.

Clin Cancer Res. 2004 Aug 15;10(16):5367-74.


Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM.

J Natl Cancer Inst. 2004 Mar 17;96(6):456-65.


Dose density by any other name.

Hryniuk W, Ragaz J, Peters W.

J Clin Oncol. 2004 Feb 15;22(4):750-1; author reply 751-3. No abstract available.


Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.

Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB, Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, Dunn SE.

Cancer Res. 2004 Jan 1;64(1):286-91.


Increased use of adjuvant regional radiotherapy for node-positive breast cancer in British Columbia.

Chua B, Olivotto IA, Weir L, Kwan W, Truong P, Ragaz J.

Breast J. 2004 Jan-Feb;10(1):38-44.


EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Schuuring E, Yu DS, Venkitaraman A, Ponder B, Doherty A, Aparicio S, Bentley D, Theillet C, Ponting CP, Caldas C, Kouzarides T.

Cell. 2003 Nov 26;115(5):523-35.


Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer.

Bryce C, Kennecke H, Chia S, Ragaz J.

J Clin Oncol. 2003 Dec 1;21(23):4465; author reply 4465-6. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk